PBAC's latest decision on Carmustine, implant: Recommended with restriction (2005). Considered for Newly-diagnosed glioblastoma multiforme as an adjunct to surgery and radiation.
PBAC outcome
Recommended with restriction
Restricted benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
Newly-diagnosed glioblastoma multiforme patients as an adjunct to surgery and radiation.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
OS, Q-TWiST
Key trials
T-301, Stupp R et al, 2005
Comparator
temozolomide
Economic model
Cost-minimisation
ICER note
Cost-minimisation basis: carmustine implant listed as equivalent to temozolomide course. Numeric ICER not calculated for the comparison; trial-based incremental costs provided but PBAC recommended cost-minimisation approach.